New Hepatitis B Treatment Offers Hope for a Functional Cure

The World Health Organization (WHO) has set an ambitious goal to eliminate the transmission of hepatitis B by 2030. In a significant step toward this objective, the laboratory GSK announced results on May 28, 2026, regarding a new treatment that could transform the management of chronic hepatitis B.

The Challenge of Chronic Hepatitis B

Chronic hepatitis B is a viral liver infection that often remains asymptomatic for years. Over time, it can progressively damage the liver, leading to severe complications such as liver failure, cirrhosis, or liver cancer.

The global burden remains high. In 2022, approximately 254 million people were living with chronic hepatitis B, and nearly 1.1 million deaths were attributed to virus-related complications, primarily liver cancer, and cirrhosis.

In France, Santé publique France estimates that around 280,000 people are living with the chronic infection. A significant number of these individuals remain unaware they are carriers, as the virus can evolve silently for years before causing organ damage.

Did You Know? According to the World Health Organization, the hepatitis B virus is extremely resistant and can survive for at least seven days on a contaminated object or surface while remaining capable of infecting an unvaccinated person.

A New Therapeutic Approach: Bepirovirsen

Hepatitis B is notoriously difficult to cure because the virus is adept at “hiding” within liver cells. Even when current treatments block its multiplication, a viral mini-reservoir often persists in the body.

View this post on Instagram about Functional Cure, Expert Insight

From Instagram — related to Functional Cure, Expert Insight

Standard treatments currently rely on nucleoside analogues. While these antivirals effectively control the infection and reduce complication risks, they rarely eliminate viral activity completely. Functional cures using these classic treatments are rare, occurring in only 1% to 4% of patients depending on the profile.

Bepirovirsen represents a new generation of treatment designed to break this therapeutic ceiling. Instead of merely controlling the virus, it targets the biological “messages” the virus uses to produce proteins and multiply in the liver.

By disrupting this process, the drug significantly reduces the presence of the hepatitis B surface antigen. When this marker disappears sustainably, it suggests the immune system may be regaining control over the virus.

Expert Insight: Samantha Carter notes that the shift from “control” to “functional cure” is the critical stake in this research. While current therapies manage the disease as a lifelong condition, the ability to potentially stop treatment and reduce transmission risks would fundamentally change the patient’s quality of life and the broader public health strategy.

Clinical Results and the “Functional Cure”

In GSK’s Phase III clinical trials, patients received the treatment for six months. Following the cessation of the drug, 19% of patients no longer had detectable virus in their blood.

LA Dept of Health launches hepatitis C elimination strategy

For patients who initially had a less active infection, the success rate reached approximately 26%. While not every patient was cured, these results represent a notable advancement over existing therapies.

Medical professionals distinguish a “functional cure” from a “complete cure.” In a functional cure, the virus is no longer detectable in blood tests and no longer causes known pathological activity, although fragments of the virus may theoretically persist at very low levels in some liver cells.

For the patient, this distinction is highly significant, as it could lead to the cessation of treatment, a decreased risk of complications, and a reduction in the risk of transmission.

Regulatory Path and Public Health

Several laboratories have explored immunotherapies, therapeutic vaccines, and combined therapies, but bepirovirsen has reached an advanced stage in Phase III trials. The U.S. Food and Drug Administration (FDA) has granted the treatment a priority evaluation procedure.

A decision regarding its status in the United States is expected by October 26, 2026. To date, no authorization has been issued in Europe.

Parallel to these medical advances, French health authorities continue to emphasize the importance of early screening. The Institut Pasteur notes that treating patients earlier can significantly limit liver damage and reduce cancer risks.

Prevention remains centered on vaccination, which has been mandatory for infants in France since 2018. This measure prevents the vast majority of new infections.

Frequently Asked Questions

What is the difference between a functional cure and a complete cure for hepatitis B?
A functional cure means the virus is no longer detectable in the blood and does not cause known pathological activity, allowing for the cessation of treatment. A complete cure would mean the total disappearance of the virus, whereas in a functional cure, viral fragments may still persist in some liver cells.

How does bepirovirsen work compared to standard antivirals?
Standard nucleoside analogues control the infection by blocking viral multiplication. Bepirovirsen targets the biological “messages” the virus uses to manufacture proteins, specifically reducing the surface antigen to help the immune system regain control.

What were the results of the bepirovirsen Phase III trials?
After six months of treatment, 19% of patients had no detectable virus in their blood. This rate increased to approximately 26% for patients who started with a less active infection.

Do you believe increased screening awareness is as critical as the development of new cures in eliminating viral hepatitis?